Abstract
Purpose: To compare the effectiveness and safety of intravenous cisplatin (DDP) and 5-fluorouracil (5-FU) alone or in combination with continuous hyperthermic peritoneal perfusion (CHPP) for the treatment of malignant ascites.Methods: In the study, 124 patients with tumour-induced malignant ascites were assign to test and control groups according to the sequence of their hospital visits. Patients in the test group were treated with intravenous DDP and 5-FU combined with CHPP, whereas patients in the control group were only treated with DDP and 5-FU. The treatments in both groups lasted for 4 weeks. Thereafter, treatment efficacy, remission of abdominal distension, ascites, Karnofsky Performance Scale (KPS) score, and incidence of adverse reactions were compared between the two groups.Results: The overall response rates of the test and control groups were 85.50 (53/62) and 35.50 % (22/62), respectively, and the difference was significant (p < 0.05). Patients in the test group showed significant reduction in abdominal distension and markedly reduced ascites compared to the controls. The improvement in KPS score was superior in the test group (p < 0.05). No treatment-associated complications, such as intestinal adhesions or obstruction and grade III or IV toxic and side reactions, were found in either group. The incidence of adverse reactions was lower in the test group than in the controls.Conclusion: Chemotherapy in combination with CHPP is safe and effective for patients with advanced malignant tumours and ascites should be promoted clinically.Keywords: Malignant ascites, Continuous hyperthermic peritoneal perfusion, Systemic intravenous chemotherapy
Highlights
Malignant ascites refers to abnormally increased liquid in the abdomen induced by diffuse lesions caused by systemic or abdominal malignancies [1,2]
To investigate the safety and effectiveness of continuous hyperthermic peritoneal perfusion (CHPP), this retrospective study analysed 124 cases of malignant ascites seen at Binzhou People’s Hospital, Shandong, China, and compared the safety and effectiveness of CHPP compared to systemic intravenous chemotherapy
Patients in the control group were treated with systemic intravenous chemotherapy comprising cisplatin (CDDP; Jinzhou Jiutai Pharmaceutical Co., Ltd., China; Batch no. 21020212) at a dose of 100 mg/m2, once every 3 weeks and 5fluorouracil
Summary
Malignant ascites refers to abnormally increased liquid in the abdomen induced by diffuse lesions caused by systemic or abdominal malignancies [1,2]. Surgery and radiotherapy cannot effectively eradicate large lesions, and intravenous chemotherapy is ineffective when using drugs that have low concentrations in the abdominal cavity [5,6]. Some researchers have developed a new treatment, namely continuous hyperthermic peritoneal perfusion (CHPP), which is based on the different tolerance of tumour and normal cells to temperature and the synergistic effects of thermo-chemotherapy [7]. To investigate the safety and effectiveness of CHPP, this retrospective study analysed 124 cases of malignant ascites seen at Binzhou People’s Hospital, Shandong, China, and compared the safety and effectiveness of CHPP compared to systemic intravenous chemotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
